CN109793745B - Application of aspirin in preparation of medicine for treating dyskinesia and pharmaceutical composition thereof - Google Patents
Application of aspirin in preparation of medicine for treating dyskinesia and pharmaceutical composition thereof Download PDFInfo
- Publication number
- CN109793745B CN109793745B CN201910069637.9A CN201910069637A CN109793745B CN 109793745 B CN109793745 B CN 109793745B CN 201910069637 A CN201910069637 A CN 201910069637A CN 109793745 B CN109793745 B CN 109793745B
- Authority
- CN
- China
- Prior art keywords
- aspirin
- parts
- dyskinesia
- medicine
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims abstract description 114
- 229960001138 acetylsalicylic acid Drugs 0.000 claims abstract description 107
- 208000012661 Dyskinesia Diseases 0.000 claims abstract description 68
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims abstract description 65
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims abstract description 63
- 229960004502 levodopa Drugs 0.000 claims abstract description 61
- 239000003814 drug Substances 0.000 claims abstract description 56
- 238000002360 preparation method Methods 0.000 claims abstract description 29
- 238000011282 treatment Methods 0.000 claims abstract description 26
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 4
- 239000003937 drug carrier Substances 0.000 claims abstract description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 229920002472 Starch Polymers 0.000 claims description 18
- 235000019698 starch Nutrition 0.000 claims description 18
- 239000008107 starch Substances 0.000 claims description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 17
- 239000011734 sodium Substances 0.000 claims description 12
- 229910052708 sodium Inorganic materials 0.000 claims description 12
- 235000019359 magnesium stearate Nutrition 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 11
- 108010010803 Gelatin Proteins 0.000 claims description 10
- 239000000796 flavoring agent Substances 0.000 claims description 10
- 235000013355 food flavoring agent Nutrition 0.000 claims description 10
- 239000008273 gelatin Substances 0.000 claims description 10
- 229920000159 gelatin Polymers 0.000 claims description 10
- 235000019322 gelatine Nutrition 0.000 claims description 10
- 235000011852 gelatine desserts Nutrition 0.000 claims description 10
- 239000008213 purified water Substances 0.000 claims description 10
- 229920001353 Dextrin Polymers 0.000 claims description 6
- 239000004375 Dextrin Substances 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- 239000003995 emulsifying agent Substances 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 6
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 6
- 235000012424 soybean oil Nutrition 0.000 claims description 6
- 239000003549 soybean oil Substances 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- 239000000375 suspending agent Substances 0.000 claims description 6
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 23
- 208000018737 Parkinson disease Diseases 0.000 abstract description 18
- 239000006187 pill Substances 0.000 abstract description 17
- 229940079593 drug Drugs 0.000 abstract description 9
- 230000007774 longterm Effects 0.000 abstract description 9
- 208000024891 symptom Diseases 0.000 abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 8
- 239000008187 granular material Substances 0.000 abstract description 7
- 239000007788 liquid Substances 0.000 abstract description 7
- 239000003826 tablet Substances 0.000 abstract description 7
- 239000002775 capsule Substances 0.000 abstract description 6
- 239000000243 solution Substances 0.000 abstract description 6
- 239000006188 syrup Substances 0.000 abstract description 6
- 235000020357 syrup Nutrition 0.000 abstract description 6
- 239000000843 powder Substances 0.000 abstract description 5
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 239000006196 drop Substances 0.000 abstract description 3
- 239000000839 emulsion Substances 0.000 abstract description 2
- 230000006872 improvement Effects 0.000 abstract description 2
- 239000007924 injection Substances 0.000 abstract description 2
- 238000002347 injection Methods 0.000 abstract description 2
- 239000000829 suppository Substances 0.000 abstract description 2
- 239000000725 suspension Substances 0.000 abstract description 2
- 208000009985 drug-induced dyskinesia Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 238000002156 mixing Methods 0.000 description 15
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 10
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 9
- 238000001035 drying Methods 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- 230000002335 preservative effect Effects 0.000 description 8
- 239000000499 gel Substances 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 239000007901 soft capsule Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 5
- 229960003638 dopamine Drugs 0.000 description 5
- 210000003194 forelimb Anatomy 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 229940085605 saccharin sodium Drugs 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 239000006180 TBST buffer Substances 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000003137 locomotive effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 4
- 238000007873 sieving Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 210000001364 upper extremity Anatomy 0.000 description 4
- -1 8 μ g) group Chemical compound 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000001259 mesencephalon Anatomy 0.000 description 3
- 230000007659 motor function Effects 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000004080 punching Methods 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- YLKRUSPZOTYMAT-YFKPBYRVSA-N 6-hydroxy-L-dopa Chemical compound OC(=O)[C@@H](N)CC1=CC(O)=C(O)C=C1O YLKRUSPZOTYMAT-YFKPBYRVSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010001541 Akinesia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000009017 Athetosis Diseases 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 241001573498 Compacta Species 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 101000643395 Escherichia phage T7 Single-stranded DNA-binding protein Proteins 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010071390 Resting tremor Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 108700016586 rat AIM Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
本方案公开了医药技术领域的阿司匹林在制备预防或治疗左旋多巴诱发异动症的药物中应用及其药物组合物。所述药物组合物以阿司匹林作为活性成分，加入药用载体或赋形剂制备为片剂、胶囊剂、颗粒剂、丸剂、滴丸剂、糖浆剂、粉剂、散剂、栓剂、滴剂、乳剂、注射液、溶液或混悬液。本发明开拓性的将阿司匹林应用于治疗长期服用左旋多巴诱发异动症，不仅对帕金森病的症状有一定的治疗效果，更大的程度上能对长期服用左旋多巴诱发异动症的延缓或者改善效果，降低了帕金森病治疗过程中因药物导致的副作用—异动症，发挥单一化合物与药物的协同作用，治疗帕金森病。因此适宜在临床中推广使用。
This scheme discloses the application of aspirin in the field of medicine technology in the preparation of a medicine for preventing or treating levodopa-induced dyskinesia and its pharmaceutical composition. The pharmaceutical composition takes aspirin as an active ingredient, and is prepared into tablets, capsules, granules, pills, dropping pills, syrups, powders, powders, suppositories, drops, emulsions, injections by adding pharmaceutically acceptable carriers or excipients. liquid, solution or suspension. The invention pioneers the application of aspirin to the treatment of dyskinesia induced by long-term use of levodopa, which not only has a certain therapeutic effect on the symptoms of Parkinson's disease, but also can delay or delay the dyskinesia induced by long-term use of levodopa to a greater extent. The improvement effect reduces the side effect of the drug-induced dyskinesia during the treatment of Parkinson's disease, and exerts the synergistic effect of a single compound and the drug to treat Parkinson's disease. Therefore, it is suitable for promotion and use in clinical practice.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to application of aspirin in preparation of a medicine for treating dyskinesia and a pharmaceutical composition of aspirin.
Background
Parkinson's Disease (PD) is a nervous system degenerative disease with progressive loss, degeneration and death of dopaminergic neurons in the substantia nigra pars compacta of the midbrain as a main pathological feature, and is frequently seen in middle-aged and elderly people. Its typical clinical manifestations are resting tremor, muscle rigidity, bradykinesia, postural instability, etc. PD is second only to alzheimer's disease, causing neuro-degeneration in the middle aged and elderly, and places a heavy burden on society and families. At present, the pathogenesis of PD is unclear, and the current treatment status is obviously limited due to poor curative effect or side effect. Therefore, finding effective treatment schemes and drugs to alleviate symptoms in PD patients is of great clinical significance.
Levodopa (L-DOPA) is still the gold standard in PD therapeutic drugs at present, is the metabolic precursor of Dopamine (DA), can enter basal ganglia through a blood brain barrier and then is decarboxylated to form dopamine, and plays a role in supplementing dopamine neurotransmitter deficiency. The levodopa can effectively improve the akinesia and the rigor state, and is commonly used for clinical combined treatment of compound levodopa or levodopa and other auxiliary medicaments. However, after 2 to 5 years of treatment with levodopa, more than half of the cases begin to exhibit fluctuation in drug efficacy. The duration of symptom improvement after each administration is shorter and shorter, and the phenomenon of hyperactivity additionally occurs, so that patients often swing back and forth between serious motion deficiency and uncontrollable hyperactivity, which is called as the dyskinesia.
LID (Levodopa-induced dyskinesia) is one of the most common complications of the long-term treatment of PD by Levodopa, mainly manifested by chorea and athetosis, and the adverse reactions seriously affect the treatment and daily life quality of PD patients. The progressive dopamine neuron loss of the nigrostriatal and the exogenous supplement of the L-DOPA are closely related to the LID, the pathogenesis of the LID is still not completely clear at present, the researches are all mechanism researches before clinic, and no LID treatment method or medicament exists in clinic at present, so that the LID prevention and treatment of PD patients still need to be solved, and a potential synergistic action strategy is combined with levodopa to possibly provide new adjuvant therapy for the Parkinson's disease.
Aspirin (Aspirin, ASA acetylsalicylic acid) is a white crystal or crystalline powder, odorless or slightly smelly with acetic acid, slightly soluble in water, readily soluble in ethanol, soluble in ether and chloroform, and acidic in aqueous solution. It has good effect in relieving mild or moderate pain, such as toothache, headache, neuralgia, muscular soreness and dysmenorrhea, and can be used for treating fever due to common cold and influenza, and rheumatalgia. In recent years, aspirin has an inhibiting effect on platelet aggregation and can prevent thrombosis, and the aspirin is clinically used for preventing transient ischemic attack, myocardial infarction, artificial heart valves and venous fistula or the formation of thrombosis after other operations. In the prior art, no report about the application of aspirin in preparing a medicine for treating the dyskinesia exists.
Disclosure of Invention
In order to solve the defects of the prior art, the invention provides the application of aspirin in the aspect of treating the dyskinesia, the application of aspirin in preparing a medicine for treating the dyskinesia and a pharmaceutical composition thereof.
The application of aspirin in the scheme in the preparation of the medicine for treating the dyskinesia refers to the application of aspirin in the preparation of the medicine for preventing or treating the levodopa-induced dyskinesia.
The aspirin is used as an active ingredient in the preparation of a medicine for treating the transaction symptom, and the medicine is prepared by adding a medicinal carrier or an excipient into the aspirin.
In the application of the aspirin in preparing the medicine for treating the dyskinesia, the medicine comprises the following raw materials in parts by weight: 10-400 parts of aspirin, 0.1-0.4 part of magnesium stearate, 4-12 parts of sodium carboxymethyl starch and 50-100 parts of microcrystalline cellulose. Mixing aspirin, sodium carboxymethyl starch and microcrystalline cellulose, sieving, mixing, adding appropriate amount of water or ethanol, granulating, drying, grading, adding magnesium stearate, and tabletting with a punching device to obtain medicinal tablet for preventing or treating levodopa induced dyskinesia.
The aspirin is applied to the preparation of the medicine for treating the dyskinesia, and the medicine comprises the following raw materials in parts by weight: 50-400 parts of aspirin, 0.1-0.3 part of magnesium stearate, 4-12 parts of sodium carboxymethyl starch and 50-100 parts of starch. The aspirin, the sodium carboxymethyl starch and the starch are uniformly mixed, a proper amount of ethanol is added for granulation, drying and granulation are carried out, the magnesium stearate is added, and then the mixture is filled into a gelatin capsule, so that the medicine capsule for preventing or treating the levodopa induced dyskinesia can be obtained.
The aspirin is applied to the preparation of the medicine for treating the dyskinesia, and the medicine comprises the following raw materials in parts by weight: 1-10 parts of aspirin and 1-10 parts of a flavoring agent, wherein the flavoring agent is dextrin or sucrose. Mixing aspirin and sucrose/dextrin uniformly, adding appropriate amount of water or ethanol to make into soft mass, sieving, granulating, drying, grading, and packaging to obtain medicinal granule for preventing or treating levodopa induced dyskinesia.
The aspirin is applied to the preparation of the medicine for treating the dyskinesia, and the medicine comprises the following raw materials in parts by weight: 10-400 parts of aspirin, 100-400 parts of polyethanol or soybean oil, 3-10 parts of a suspending agent, 3-10 parts of an emulsifier, 50-100 parts of gelatin, 10-20 parts of glycerol and 50-100 parts of purified water. Putting gelatin into a gelatin dissolving tank, adding purified water, heating at 70 ℃ to dissolve, adding glycerol, stirring uniformly, removing bubbles under vacuum, keeping the temperature and standing, uniformly mixing aspirin, polyethanol/soybean oil, an emulsifier and a suspending agent according to a proportion, putting the mixture and the prepared gelatin into a rotary capsule press, pressing into soft capsules, shaping and drying to obtain the medicinal soft capsules for preventing or treating levodopa-induced dyskinesia. In order to prolong the storage time of the medicine, a proper amount of preservative can be added in the preparation stage to prolong the shelf life of the medicine.
The aspirin is applied to the preparation of a medicine for treating the transaction symptoms, and the medicine comprises, by weight, 1-10 parts of aspirin and 20-40 parts of a matrix, wherein the matrix is at least one of polyethylene glycol, polyvinylpyrrolidone, stearic acid and glyceryl monostearate. Adding water into aspirin, making into uniform paste, adding molten matrix solution, heating and melting to obtain clear liquid, adding into preheated dripping pill machine, controlling dripping temperature and speed, dripping into condensate, making into pill, sucking off the condensate, collecting dripping pill, and placing into dryer to obtain the medicinal dripping pill for preventing or treating levodopa induced dyskinesia. In order to improve the roundness of the dripping pill, methyl silicone oil can be used as condensate.
The aspirin is applied to the preparation of the medicine for treating the dyskinesia, and the medicine comprises the following raw materials in parts by weight: 1-20 parts of aspirin, 1.5 parts of sodium carboxymethyl cellulose, 0.1 part of saccharin sodium and 100 parts of purified water. Dispersing sodium carboxymethyl cellulose in hot water, cooling, mixing with water suspension containing aspirin and saccharin sodium, blending the solution into required volume, mixing uniformly, sterilizing, and packaging to obtain the medicinal syrup for preventing or treating levodopa induced dyskinesia. In order to improve the taste of the medicine, a flavoring agent can be added according to the actual situation; in order to increase the shelf life of the drug, a suitable amount of preservative may be added.
In another aspect, the present invention provides a pharmaceutical composition comprising aspirin as an active ingredient, in combination with a pharmaceutically acceptable carrier or excipient, for preventing or treating levodopa-induced dyskinesia.
Preferably, the pharmaceutical composition is prepared into tablets, capsules, granules, pills, drop pills, syrups, powders, suppositories, drops, emulsions, injections, solutions or suspensions.
Preferably, the pharmaceutical composition is prepared into tablets, soft capsules, hard capsules, granules, pills, dripping pills or syrups.
The invention has the beneficial effects that: the invention pioneers the aspirin in the treatment of the L-dopa induced dyskinesia after long-term administration, has a certain treatment effect on the symptoms of the Parkinson's disease, can delay or improve the effect of the L-dopa induced dyskinesia after long-term administration to a greater extent, reduces the side effect of the dyskinesia caused by the administration of drugs in the Parkinson's treatment process, and plays a synergistic effect of a single compound and the drugs to treat the Parkinson's disease. Therefore, the utility model is suitable for clinical application.
Drawings
FIG. 1 is a graph of the effect of aspirin on the oral facial AIM score in levodopa-induced dyskinesia rats;
FIG. 2 is a graph of the effect of aspirin on the upper limb AIM score of levodopa-induced dyskinesia rats;
FIG. 3 is a graph of the effect of aspirin on levodopa-induced dyskinesia rat axial AIM score;
FIG. 4 is a graph of the effect of aspirin on total AIM score in levodopa-induced dyskinesia rats;
FIG. 5 is a graph of the effect of aspirin on the locomotor ability of levodopa-induced dyskinesia rats;
FIG. 6 is a graph showing the effect of aspirin on Levodopa-induced dyskinesia rat inflammatory factors.
Detailed Description
The following is further detailed by way of specific embodiments:
the reference numerals in the drawings of the specification have the meanings given below: m represents 6-OHDA (6-hydroxydopa); ASA stands for aspirin, L-DOPA for levodopa; # denotes P <0.05 in comparison to group M in three other groups; ω represents three additional groups compared to the M + ASA group: Ψ represents three additional groups compared to the M + L-DOPA group: p is less than 0.05.
Example 1
The preparation method of the medicinal tablet for preventing or treating the levodopa-induced dyskinesia comprises the following steps: taking 10-400 mg of aspirin, 0.1-0.40 mg of magnesium stearate, 4-12 mg of sodium carboxymethyl starch, 50-100 mg of microcrystalline cellulose, mixing the aspirin, the sodium carboxymethyl starch and the microcrystalline cellulose, sieving, uniformly mixing, adding a proper amount of water or ethanol for granulation, drying, granulating, adding the magnesium stearate, and pressing the granules into tablets by using a punching device to obtain the aspirin tablet. The dosage is as follows: the dosage is 5-50mg/kg based on aspirin active ingredient. In this example, 193 mg of aspirin, 0.15 mg of magnesium stearate, 5.8 mg of sodium carboxymethyl starch, and 63 mg of microcrystalline cellulose were selected.
Example 2
The preparation method of the medicine capsule for preventing or treating the levodopa-induced dyskinesia comprises the following steps: taking 50-400 mg of aspirin, 0.1-0.30 mg of magnesium stearate, 4-12 mg of sodium carboxymethyl starch and 50-100 mg of starch, uniformly mixing the aspirin, the sodium carboxymethyl starch and the starch, adding a proper amount of ethanol for granulation, drying, granulating, adding the magnesium stearate, and filling into gelatin capsules to obtain the aspirin-modified starch. The dosage is as follows: the dosage is 5-50mg/kg based on aspirin active ingredient. In this example, 326 mg of aspirin, 0.21 mg of magnesium stearate, 5mg of sodium carboxymethyl starch, and 86 mg of starch were selected.
Example 3
The preparation method of the medicinal granules for preventing or treating the levodopa-induced dyskinesia comprises the following steps: taking 1-10 g of aspirin, 1-10 g of dextrin or sucrose, and a proper amount of a flavoring agent and a sweetening agent, uniformly mixing the aspirin, the sucrose/dextrin, the flavoring agent and the sweetening agent, adding a proper amount of water or ethanol to prepare a soft material, sieving and granulating, drying, finishing granules, and subpackaging to obtain the aspirin-modified aspirin soft capsule. The dosage is as follows: the dosage is 5-50mg/kg based on aspirin active ingredient. In this example, 6.8 g of aspirin, 3.6 g of dextrin or sucrose, and appropriate amounts of flavoring agent and sweetener are selected.
Example 4
A preparation method of a medicinal soft capsule for preventing or treating levodopa-induced dyskinesia comprises the following steps of taking 10-400 mg of aspirin, 100-400 mg of polyethanol or soybean oil, 3-10 mg of a suspending agent, 3-10 mg of an emulsifier, 50-100 mg of gelatin, 10-20 mg of glycerol, 50-100 mg of purified water and a proper amount of a preservative, placing the gelatin in a gelatin dissolving tank, adding purified water, heating at 70 ℃ to dissolve, adding the glycerol and the preservative, stirring uniformly, removing bubbles in vacuum, keeping the temperature and standing, mixing the aspirin, the polyethanol/soybean oil, the emulsifier and the suspending agent uniformly according to a proportion, placing the mixture and the prepared gelatin in a rotary capsule press, pressing into soft capsules, shaping, and drying to obtain the levodopa-induced dyskinesia soft capsule. The dosage is as follows: the dosage is 5-50mg/kg based on aspirin active ingredient. In this example, 269 mg of aspirin, 251 mg of polyethanol or soybean oil, 5mg of suspending agent, 4 mg of emulsifier, 79 mg of gelatin, 13 mg of glycerol, 85 mg of purified water and an appropriate amount of preservative were selected.
Example 5
A preparation method of a medicinal dripping pill for preventing or treating levodopa-induced dyskinesia comprises the following steps of taking 1-10 mg of aspirin, 20-40 mg of a matrix and a proper amount of methyl silicone oil, adding water into the aspirin to prepare uniform paste, adding a molten matrix solution, heating and melting to obtain a clear liquid, pouring the clear liquid into a preheated dripping pill device, controlling the dripping temperature and speed, dripping the clear liquid into a methyl silicone oil condensate, forming pills, sucking the condensate, collecting the dripping pills, and placing the dripping pills into a dryer to obtain the dripping pills. The dosage is as follows: the dosage is 5-50mg/kg based on aspirin active ingredient. In this example, 8.6 mg of aspirin, 32 mg of a substrate and an appropriate amount of methylsilicone oil were selected.
Example 6
A preparation method of a medicinal syrup for preventing or treating levodopa-induced dyskinesia comprises the following steps of taking 1-20 g of aspirin, 1.5 g of sodium carboxymethyl cellulose, 0.1 g of saccharin sodium, a proper amount of a flavoring agent, a proper amount of a preservative and 100 ml of purified water, dispersing the sodium carboxymethyl cellulose in hot water, cooling, mixing with an aqueous suspension containing the aspirin, the saccharin sodium, the flavoring agent and the preservative, blending the solution into a required volume, uniformly mixing, sterilizing and subpackaging to obtain the levodopa-induced dyskinesia syrup. The dosage is as follows: the dosage is 5-50mg/kg based on aspirin active ingredient. In this example, 16.3 g of aspirin, 1.5 g of sodium carboxymethyl cellulose, 0.1 g of saccharin sodium, a proper amount of flavoring agent, a proper amount of preservative, and 100 ml of purified water are selected.
In order to ensure the science, the reasonability and the effectiveness of the technical scheme of the invention, the inventor carries out a series of experiments.
Experimental materials and instruments
1.1 Experimental animals
SD male rats, with a weight of 200-.
1.2 Main instrumentation
Rat brain stereotaxic apparatus (Narishige, USA), OLYMPUS optical microscope (OLYMPUS, Japan), BSS-110 electronic analytical balance (electronic balance, Inc. Sadolis, Beijing), Milli QA pure water processor (Millipore, Inc.), etc.
1.3 Main test reagents
Aspirin with purity greater than or equal to 98% (Sigma company); levodopa with purity not less than 98 percent (Sigma company), BCA kit, RIPA lysate, beta-actin mouse anti-rat polyclonal antibody, COX-2, IL-6 and iNOS polyclonal antibody.
Second, Experimental methods
2.1 Experimental groups
30 SD rats, male, with a weight of 200- & lt250 g, were randomly divided into 5 groups of 6 rats each, set as: blank group, 6-OHDA (6-OHDA, 8 μ g) group, 6-OHDA + levodopa (L-DOPA, 25mg/kg) group, 6-OHDA + ASA (aspirin, 10mg/kg) group, 6-OHDA + L-DOPA (25mg/kg) + aspirin (10mg/kg) group. After 21 days of molding, ASA is administered by gavage and L-DOPA is injected intraperitoneally for 21 days.
2.2 preparation of animal models
SD rats were anesthetized with 7% chloral hydrate (0.5mL/100g) under sterile conditions with bregma as the origin of coordinates, bregma 5.2mm posterior, midline 2.2mm, subdural 8.0mm, and 4. mu.L of 6-OHDA at 2. mu.g/. mu.L concentration injected at a constant rate.
2.3 behavioral experiments
2.3.1 AIM score
Rats were subjected to AIM scoring on days 7, 14, 21 and evaluated every 30min for 4 times at 120min after dosing. And A IM scoring: the evaluation was carried out in 4 parts (upper arm AIM, orofacial AIM and axial AIM), each part was graded by 5 (0-4) according to the presence or absence and severity: theoretically, the maximum mean integral of 1 rat after 1 administration is 16 points. 0: none; 1: 50% of the time of no observation for the presence of AIM; 2: AIM presence greater than 50% of observation time; 3: persisting, stopping the stimulation; 4: persisting, the stimulus cannot stop it.
2.3.2 step by step experiments
Rat forelimb motor function was measured before and 30min after each levodopa treatment: the experimenter fixes the back half part and hind limb of the rat body with one hand to lift the ground, fixes the forelimb on one side with the other hand to land the other forelimb, moves the rat with the direction of the rat's forehand inclined to one side (moving 90cm in 5 s), records the number of the forelimb contact and lift-off steps on the land side of the rat when moving, and alternately measures the number of the steps of the forelimbs on both sides
2.4 taking materials
After the rats in each group are respectively narcotized with 7% chloral hydrate, the abdominal cavity is opened, the abdominal aorta is clamped, the thoracic cavity is cut open, the heart is fully exposed, the transirrigation needle is inserted into the aorta through the apex cordis, the right auricle is fixed and cut open by hemostatic forceps, 0.1mol/L PBS liquid is perfused at a certain speed until the blood in the brain is washed clean, the head is directly cut off, the brain is taken out, and the midbrain is separated and stored at the temperature of minus 80 ℃.
2.5 protein assay
1) Protein extraction: taking out the midbrain, adding appropriate amount of prepared RIPA lysate, grinding, homogenizing, standing on ice for 20min, centrifuging at 12000 rpm for 15min at 4 deg.C, collecting supernatant, and storing at-80 deg.C.
2) The BCA method detects the protein concentration of the sample.
3) Sample protein denaturation: and determining the protein quality of the sample detection according to the protein concentration and the volume of each group of samples, and calculating the detection volume of each group of samples under the condition of the same quality of protein.
4) Sample adding: and (3) taking out 10% NuPAGE gel, fixing the NuPAGE gel in an electrophoresis tank, filling electrophoresis liquid in the electrophoresis tank, vertically pulling out a comb on the gel, respectively adding the detection samples into gel holes, covering the electrophoresis tank, connecting positive and negative electrodes, and starting electrophoresis.
5) Electrophoresis: firstly, adjusting the voltage to 70V, carrying out electrophoresis for about 40min, after the Maker strip begins to be separated, adjusting the voltage to 110V until the Maker strip reaches the bottom of the lower layer gel, and stopping electrophoresis.
6) Electric conversion: performing electric transfer by using semi-dry transfer, cutting gel with required molecular weight, placing the gel into an electric transfer box according to the sequence of filter paper-polyvinylidene fluoride membrane (PVDF membrane) -gel-filter paper, setting the voltage at 25V, setting the voltage at 1.0A, and starting the electric transfer within 30 min.
7) Washing: taking out the PVDF membrane, washing with TBST once for 10min and 3 times;
8) and (3) sealing: sealing with 5% skimmed milk powder for 3 hr, washing with TBST for 10min for 3 times;
9) adding a primary antibody: incubating at 4 ℃ overnight, washing with TBST once for 10min and 3 times;
10) adding a secondary antibody: incubating for 1h at room temperature, washing with TBST for 10min once and 3 times;
11) exposing;
12) and (4) carrying out gray level calculation on the strip by adopting a Quantity One quantitative analysis software system.
2.6 statistical analysis of data
The experimental data were statistically analyzed using SPSS21.0 statistical software, all data are expressed as means. + -. standard deviation, group differences in mean were compared using one-way analysis of variance (ANOVA), group differences in mean were compared using the LSD method for all means, variance was varied, group differences in mean were compared using Dunnett's T3, and P <0.05 was statistically significant.
Third, experimental results
1. Effect of Aspirin on Levodopa-induced dyskinesia rat AIM score
The evaluation was carried out by dividing into 4 parts (upper limb AIM, orofacial AIM, axial AIM) (fig. 1-3), and the results of the total division are shown in the figure (fig. 4). The animals had increased AIM scores at various time points after L-DOPA administration compared to the 6-OHDA group, with statistical differences (P < 0.05) with increasing AIM scores at longer administration times; while ASA treatment improved AIM scores in rats to some extent, on days 1, 7, 14 and 21, there was a trend toward a decrease in AIM scores for upper limbs, orofacial AIM and axial AIM, all with statistical differences (P < 0.05). Thus, it is known that administration of aspirin improves dyskinesia caused by long-term administration of levodopa.
2. Effect of Aspirin on Levodopa-induced dyskinesia rat motility
The locomotor ability of the rats was tested by the step-by-step experiment, and as shown in fig. 5, the locomotor ability of the rats was significantly improved by administration of levodopa (P < 0.05), and the locomotor function of the rats was not improved by administration of aspirin alone, as compared with the 6-OHDA group. However, after the aspirin and the levodopa are used together, the motor function of a rat is improved, and experimental results prove that the aspirin does not influence the curative effect of the levodopa while improving the abnormal symptoms.
3. Effect of Aspirin on Levodopa-induced dyskinesia rat inflammatory factor
The occurrence of dyskinesia is closely related to the release of inflammatory factors, and the results are shown in fig. 6. Compared with rats in the M group, the rats have increased inflammatory factor expression by long-term administration of levodopa, and have statistical difference; however, after aspirin administration, the release of inflammatory factors was reduced to some extent, and there was a statistical difference compared with the M + L-DOPA group. Therefore, it is known that aspirin administration can reduce the release of inflammatory factors in rats with levodopa-induced dyskinesia.
To summarize: from the perspective of an overall experiment, the aspirin is verified to delay or treat the dyskinesia caused by long-term levodopa administration and improve the motor function by AIM scoring and other methods. Thus proving that the aspirin has a treatment effect on the dyskinesia and can delay the occurrence and the development of the dyskinesia.
The invention has the advantages that: the invention provides an application of aspirin, namely an application of aspirin in preparation of a medicine for preventing or treating levodopa-induced dyskinesia. Aspirin has effects of preventing and treating Levodopa induced dyskinesia.
(1) Aspirin can improve the AIM score of rats to a certain extent, obviously reduce oral and facial, forelimb AIM and axial AIM after administration, and can improve the dyskinesia caused by long-term administration of levodopa.
(2) The aspirin does not influence the effect of levodopa on treating PD while improving the dyskinesia.
(3) Aspirin can reduce the expression of inflammatory factors of rats with levodopa-induced dyskinesia.
Aspirin can improve the clinical symptoms of the dyskinesia and delay the appearance time of the dyskinesia. The traditional Chinese medicine composition has a certain treatment effect on symptoms of the Parkinson's disease, can delay or improve the dyskinesia induced by long-term administration of levodopa to a greater extent, reduces the dyskinesia which is a side effect caused by medicines in the Parkinson treatment process, and plays a synergistic effect of a single compound and the medicines to treat the Parkinson's disease. Is suitable for being popularized and used in clinic.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910069637.9A CN109793745B (en) | 2019-01-24 | 2019-01-24 | Application of aspirin in preparation of medicine for treating dyskinesia and pharmaceutical composition thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910069637.9A CN109793745B (en) | 2019-01-24 | 2019-01-24 | Application of aspirin in preparation of medicine for treating dyskinesia and pharmaceutical composition thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109793745A CN109793745A (en) | 2019-05-24 |
| CN109793745B true CN109793745B (en) | 2021-05-25 |
Family
ID=66560389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910069637.9A Active CN109793745B (en) | 2019-01-24 | 2019-01-24 | Application of aspirin in preparation of medicine for treating dyskinesia and pharmaceutical composition thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109793745B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004085712A2 (en) * | 2003-03-24 | 2004-10-07 | Penn State Research Foundation | Multi-functional polymeric materials and their uses |
| CN107624067A (en) * | 2015-03-06 | 2018-01-23 | 奥斯拜客斯制药有限公司 | Method for treating Abnormal involuntary movement obstacle |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102525876B (en) * | 2010-12-15 | 2014-03-12 | 西安力邦医药科技有限责任公司 | Aspirin solid dispersion, as well as preparation method, pharmaceutical composition and use thereof |
| CN102641254B (en) * | 2012-05-07 | 2013-10-09 | 山东新华制药股份有限公司 | Preparation method of aspirin enteric-coated sustained-release preparation |
-
2019
- 2019-01-24 CN CN201910069637.9A patent/CN109793745B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004085712A2 (en) * | 2003-03-24 | 2004-10-07 | Penn State Research Foundation | Multi-functional polymeric materials and their uses |
| US20050169882A1 (en) * | 2003-03-24 | 2005-08-04 | Lowe Tao L. | Multi-functional polymeric materials and their uses |
| CN107624067A (en) * | 2015-03-06 | 2018-01-23 | 奥斯拜客斯制药有限公司 | Method for treating Abnormal involuntary movement obstacle |
Non-Patent Citations (1)
| Title |
|---|
| 链球菌感染后风湿热和风湿性心脏病;高路等;《临床儿科杂志》;20061231;第24卷(第6期);第461-463页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109793745A (en) | 2019-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3152326C (en) | Preparation of transmucosal psychoactive alkaloid composition | |
| CN101926853A (en) | Pharmaceutical composition with blood sugar reducing effect, preparation method and application thereof | |
| WO2008122190A1 (en) | The composition comprising l-carnitine or derivatives thereof and its use | |
| CN108143733B (en) | Anesthetic analgesic pharmaceutical composition and preparation method thereof | |
| CN109793745B (en) | Application of aspirin in preparation of medicine for treating dyskinesia and pharmaceutical composition thereof | |
| CN102716135B (en) | Lupenone prevents in preparation or treats the application in the product of diabetes | |
| CN103108639B (en) | Composition of active ingredient of traditional chinese medicine and use thereof | |
| RU2237475C1 (en) | Combined preparation to remove symptoms of catarrhal diseases and grippe (variants) | |
| CN111939158A (en) | Application of stephanine and derivatives thereof in preparation of medicines for treating neurodegenerative diseases | |
| CN116019854B (en) | Application of mulberry extract in preparing medicine for preventing and/or treating hepatobiliary diseases | |
| CN108042555B (en) | Application of a kind of icariin | |
| CN117122629A (en) | Application of mulberry extract in preparation of drugs for improving and/or treating thyroid diseases | |
| KR20210061390A (en) | Rotomeric isomer of 4-alkyl-5-heteroaryl-3H-1,2-dithiol-3-thione | |
| CN104490876A (en) | Application of berberine hydrochloride in preparation of medicine used for preventing and/or treating acute hepatic failure | |
| CN100563682C (en) | A kind of pharmaceutical composition of making by Folium Crataegi and Radix Rhodiolae and preparation method thereof | |
| CN109260205B (en) | Application of tetrandrine in preparation of medicine for resisting diabetes and hypertension | |
| CN102389434A (en) | Medicinal composition for treating ischemic cerebrovascular disease, and preparation method thereof | |
| CN106562985A (en) | Medicinal health care applications of linarin | |
| CN107233370B (en) | Application of Rhododendron mosaic in the preparation of medicines for preventing and/or treating neurodegenerative diseases and medicines | |
| CN111920835A (en) | Application of medicinal preparation in preparing medicament for treating senile dementia | |
| JP7706025B2 (en) | Preparation for treating and/or preventing polycystic ovary syndrome and method for producing same | |
| CN104906501A (en) | Chinese herbal component composition for treatment of psoriasis | |
| CN103800712B (en) | A kind of for preventing and/or the Chinese medicine composition treating cerebral ischemia reperfusion injury and preparation method thereof | |
| CN100506235C (en) | A kind of freeze-dried preparation for treating cerebrovascular disease | |
| CN116270851A (en) | Preparation method of Dahongpao extract and application in blood pressure lowering medicine or food |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 563000 Dalian Road, Guizhou, China, No. 201, No. Applicant after: ZUNYI MEDICAL University Address before: 563000 No. 201 Dalian Road, Huichuan District, Zunyi City, Guizhou Province Applicant before: ZUNYI MEDICAL University |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |